Mayeule Legrand

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures

Christine Katlama, Stéphanie Dominguez, Karine Gourlain et al. · AIDS · 2004 · 90 citations

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +16

Pharmacokinetics of Abacavir in HIV-1-Infected Patients with Impaired Renal Function

Hassane Izzedine, Vincent Launay‐Vacher, Guy Aymard et al. · ˜The œNephron journals/Nephron journals · 2001 · 37 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects

Ivan Berlin, Dominique Warot, Guy Aymard et al. · European Journal of Clinical Pharmacology · 2001 · 28 citations

Medicine, Pharmacokinetics, Pharmacology +8

Population pharmacokinetic analysisof lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART

Xavière Panhard, Mayeule Legrand, Anne‐Marie Taburet et al. · European Journal of Clinical Pharmacology · 2007 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Virological and pharmacological factors associated with virological response to salvage therapy after an 8‐week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)

Constance Delaugerre, Gilles Peytavin, Stéphanie Dominguez et al. · Journal of Medical Virology · 2005 · 24 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17